Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial
Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for the disease. To determine the effect of bamlanivimab monotherapy and combination therapy with bamlanivimab and etesevimab on severe acute respiratory syndrome coronavirus 2. The BLAZE-1 study is a randomized phase 2/3 trial at 49 US centers. The primary endpoint was a change in SARS-CoV-2 log viral load on day 11. No significant difference in viral load reduction was o
